Releases Geral
Boehringer Ingelheim and WHO Foundation join forces to promote equitable access to healthcare and increase efforts for suicide prevention
AGÊNCIA DE COMUNICAÇÃO Conteúdo de responsabilidade da empresa 15 de outubro de 2024
Boehringer Ingelheim Limited
Boehringer Ingelheim, a biopharmaceutical company active in both human and animal health, in partnership with WHO Foundation, today pledged USD 5 million to advance access to quality healthcare services for all, with a special focus on vulnerable populations in the Americas who are at greater risk of suicide.
Through this partnership with the WHO Foundation, Boehringer Ingelheim will provide financial support to WHOs Fourteenth General Program of Work, spanning from 2025 to 2028, contributing to WHOs Investment Round. Additionally, Boehringer Ingelheim and the WHO Foundation will support evidence-based interventions in the Americas to promote equitable access to healthcare and prevent suicide.
WHOs mission of Health for All can only be achieved with the combined commitment of the public and private sectors. Boehringer Ingelheim recognizes this and is meeting WHOs call to action by making a pledge of predictable and flexible resources, says WHO Foundation CEO, Anil Soni. “Moreover, by donating to WHO for the first time, Boehringer Ingelheim is broadening the base of WHOs supporters, affirming WHOs essential role to global public health.
Limited or no access to help for patients is alarming, especially in underserved communities. We truly look forward to our collaboration with the WHO Foundation and its partners as we want to increase access to life-saving healthcare services,” says Médard Schoenmaeckers, Global Head of Corporate Affairs at Boehringer Ingelheim.
The partnership between Boehringer Ingelheim and WHO Foundation aims to elevate the importance of financing equitable healthcare services to address mental health globally. Boehringer Ingelheim has made a long-term commitment to invest in mental health research with the aspiration of redefining healthcare to improve outcomes for people living with serious mental illnesses. Boehringer Ingelheim also supports a range of related private initiatives such as the Friendship Bench, an evidence-based life-saving mental health program in Zimbabwe, which enlists grandmothers as volunteer therapists.
Both WHO Foundation and Boehringer Ingelheim are committed to mobilizing more resources to improve equitable access to mental health. Boehringer Ingelheim hopes that partnering with the WHO Foundation will catalyze greater support from across industry and philanthropy and effectively pool resources to improve outcomes for people worldwide. Together, they aim to create lasting impact, ensuring greater access to care and support for those who need it most.
Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industrys top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at Boehringer Ingelheim – Life Forward / Boehringer Ingelheim (boehringer-ingelheim.com).
WHO Foundation
The WHO Foundation is an independent global organization working to improve health equity around the world. We connect donors with those on the frontlines of health challenges to create lasting change. The Foundation forms impactful partnerships and develops innovative ways to fund important health projects. Our goal is to inspire private support and build strong partnerships that advance WHOs mission to improve health and protect vulnerable communities. For more information, visit: WHO Foundation.
A OESP nao e(sao) responsavel(is) por erros, incorrecoes, atrasos ou quaisquer decisoes tomadas por seus clientes com base nos Conteudos ora disponibilizados, bem como tais Conteudos nao representam a opiniao da OESP e sao de inteira responsabilidade da GlobeNewswire
Leia também
-
Releases Geral Número de startups cresce e chega a mais de 12 mil no Brasil
19 de junho de 2024(DINO - 10 jun, 2024) - As startups tornaram-se comuns em vários setores da economia (como educação, saúde e transporte) e já chegam a mais de 1
Saiba Mais -
Releases Geral Como ansiedade, depressão e burnout impactam empresas
19 de junho de 2024(DINO - 19 jun, 2024) - A sociedade contemporânea, marcada por um ritmo acelerado e mudanças profundas nas percepções de objetivos e propósitos,
Saiba Mais -
Releases Geral Enxaqueca afeta mais de 30M, mas ainda é pouco compreendida
28 de maio de 2024São Paulo SP--(DINO - 28 mai, 2024) - Uma das doenças mais incapacitantes do mundo, a enxaqueca ainda enfrenta muito estigma e falta de compreensão na sociedade, ape
Saiba Mais